Last reviewed 2026-04-20 · How we verify
Home › Drugs › Tris Pharma, Inc. › Amphetamine Extended Release Suspension [Dyanavel] Amphetamine Extended Release Suspension [Dyanavel]
At a glance
Generic name Amphetamine Extended Release Suspension [Dyanavel] Also known as DYANAVEL XR, amphetamine extended release oral suspension Sponsor Tris Pharma, Inc. Modality Small molecule Phase FDA-approved
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/amphetamine-extended-release-suspension-dyanavel · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.